Bonesupport Holding AB (publ)

BATS-CHIXE:BONEXS Stock Report

Market Cap: SEK 22.5b

Bonesupport Holding Valuation

Is BONEXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BONEXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 515.46
Fair Value
26.7% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: BONEXS (SEK377.6) is trading below our estimate of fair value (SEK515.46)

Significantly Below Fair Value: BONEXS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BONEXS?

Key metric: As BONEXS is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BONEXS. This is calculated by dividing BONEXS's market cap by their current revenue.
What is BONEXS's PS Ratio?
PS Ratio27.7x
SalesSEK 814.46m
Market CapSEK 22.54b

Price to Sales Ratio vs Peers

How does BONEXS's PS Ratio compare to its peers?

The above table shows the PS ratio for BONEXS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.6x
GNS Genus
1.7x3.4%UK£1.1b
AVCT Avacta Group
7.9x0.4%UK£179.3m
OXB Oxford Biomedica
4.5x21.2%UK£439.6m
BVXP Bioventix
12.3xn/aUK£167.0m
BONEXS Bonesupport Holding
27.7x33.8%SEK 22.5b

Price-To-Sales vs Peers: BONEXS is expensive based on its Price-To-Sales Ratio (27.7x) compared to the peer average (6.6x).

Price to Sales Ratio vs Industry

How does BONEXS's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.4%US$1.43b
OXB Oxford Biomedica
4.5x21.2%US$549.32m
TRX Tissue Regenix Group
1.7x15.1%US$52.51m
AREC Arecor Therapeutics
4.5x2.5%US$27.60m
No. of Companies7PS020406080100+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BONEXS is expensive based on its Price-To-Sales Ratio (27.7x) compared to the European Biotechs industry average (8.4x).

Price to Sales Ratio vs Fair Ratio

What is BONEXS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BONEXS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio27.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BONEXS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BONEXS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
SEK 422.33
0%
4.9%SEK 450.00SEK 400.00n/a3
Jan ’26n/a
SEK 402.33
0%
2.8%SEK 417.00SEK 390.00n/a3
Dec ’25n/a
SEK 362.33
0%
16.4%SEK 417.00SEK 280.00n/a3
Nov ’25n/a
SEK 345.67
0%
16.2%SEK 417.00SEK 280.00n/a3
Oct ’25n/a
SEK 323.33
0%
9.6%SEK 350.00SEK 280.00n/a3
Sep ’25SEK 298.80
SEK 323.33
+8.2%
9.6%SEK 350.00SEK 280.00n/a3
Aug ’25n/a
SEK 323.33
0%
9.6%SEK 350.00SEK 280.00n/a3
Jul ’25n/a
SEK 297.67
0%
4.6%SEK 313.00SEK 280.00n/a3
Jun ’25n/a
SEK 292.67
0%
5.0%SEK 313.00SEK 280.00n/a3
May ’25n/a
SEK 292.67
0%
5.0%SEK 313.00SEK 280.00n/a3
Apr ’25n/a
SEK 273.67
0%
4.6%SEK 285.00SEK 256.00n/a3
Mar ’25SEK 203.00
SEK 257.00
+26.6%
7.2%SEK 280.00SEK 235.00n/a3
Feb ’25n/a
SEK 257.00
0%
7.2%SEK 280.00SEK 235.00n/a3
Jan ’25n/a
SEK 245.50
0%
4.3%SEK 256.00SEK 235.00n/a2
Dec ’24n/a
SEK 245.50
0%
4.3%SEK 256.00SEK 235.00n/a2
Nov ’24SEK 147.00
SEK 166.50
+13.3%
3.9%SEK 173.00SEK 160.00n/a2
Oct ’24n/a
SEK 166.50
0%
3.9%SEK 173.00SEK 160.00n/a2
Sep ’24n/a
SEK 166.50
0%
3.9%SEK 173.00SEK 160.00SEK 298.802
Aug ’24n/a
SEK 166.50
0%
3.9%SEK 173.00SEK 160.00n/a2
Jul ’24SEK 123.00
SEK 154.00
+25.2%
9.1%SEK 168.00SEK 140.00n/a2
Jun ’24n/a
SEK 154.00
0%
9.1%SEK 168.00SEK 140.00n/a2
May ’24SEK 101.70
SEK 141.50
+39.1%
18.7%SEK 168.00SEK 115.00n/a2
Apr ’24SEK 83.90
SEK 141.50
+68.7%
18.7%SEK 168.00SEK 115.00n/a2
Mar ’24SEK 86.65
SEK 141.50
+63.3%
18.7%SEK 168.00SEK 115.00SEK 203.002
Feb ’24SEK 87.40
SEK 123.50
+41.3%
6.9%SEK 132.00SEK 115.00n/a2
Jan ’24SEK 80.15
SEK 123.50
+54.1%
6.9%SEK 132.00SEK 115.00n/a2
Analyst Price Target
Consensus Narrative from 3 Analysts
SEK 465.48
Fair Value
18.9% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/25 21:08
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bonesupport Holding AB (publ) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maria Vara FernándezBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Jonas PeciulisEdison Investment Research